

Clarke

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 11-179296-00007-0000

Fecha: 2013-08-28 14:55:25 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 523 RESPUESTA Folios: 51

1

P-3193

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

DIVISION DE NUEVAS CREACIONES

E. S. D.

Re: Expediente No. **11-179296**

Solicitud de patente a nombre de **AGIOS PHARMACEUTICALS, INC.**

Yo, SILVANA MARIA LOPEZ DIAZ, identificada como aparece al pie de mi firma, domiciliada en la carrera 11 No. 86-53, piso 6, obrando como apoderada de **AGIOS PHARMACEUTICALS, INC.**, domiciliado en Massachusetts, Estados Unidos de América, solicitante de la patente de la referencia, en respuesta al oficio No. 6907 notificado por fijación en lista el 23 de abril de 2013, cuyo término fue prorrogado mediante escrito radicado el 28 de junio de 2013, me permito manifestar:

1. Con fundamento en la facultad que confiere el artículo 34 de la Decisión 486 al solicitante para modificar la solicitud de patente en cualquier momento del trámite, presento junto con este memorial un nuevo capítulo reivindicatorio el cual comprende 1 a 20 reivindicaciones y reemplaza completamente el capítulo anterior.

En cuanto a estas modificaciones, me permito decir que las mismas no amplían de ninguna manera la materia objeto de la presente solicitud y se realizaron con el ánimo de superar las objeciones de patentabilidad, claridad, unidad, novedad y nivel inventivo planteadas por el examinador en su concepto técnico.

No se incluye un recibo de tasas porque el nuevo capítulo tiene menos reivindicaciones que el presentado originalmente.

2. Excepciones a la patentabilidad

El solicitante presenta un nuevo capítulo reivindicatorio, con el cual se consideran subsanadas las objeciones presentadas por el examinador a la patentabilidad del mismo.

3. Reivindicaciones de uso

El solicitante presenta un nuevo capítulo reivindicatorio, con el cual se consideran subsanadas las objeciones presentadas por el examinador a la patentabilidad del mismo.

P-3193

4. Claridad de la solicitud

El examinador objeta el título de la solicitud, argumentando que el mismo no describe de manera adecuada el objeto de la solicitud. Con el fin de subsanar esta objeción, el solicitante propone el siguiente título: “COMPUESTOS MODULADORES DE PIRUVATO CINASA M2 Y SALES, SOLVATOS E HIDRATOS DE LOS MISMOS”.

El solicitante presenta un nuevo capítulo reivindicatorio, con el cual se consideran subsanadas las objeciones presentadas por el examinador a la claridad del mismo.

5. Falta de Unidad de invención

El solicitante presenta un nuevo capítulo reivindicatorio, con el cual se consideran subsanadas las objeciones presentadas por el examinador a la unidad del mismo.

6. Falta de Novedad

El examinador objeta la novedad de la presente solicitud a la luz de lo divulgado por las anterioridades D1 – D5. Con el fin de subsanar las objeciones del examinador, el solicitante modifica la reivindicación 1 para definir A como quinolinilo opcionalmente sustituido. De acuerdo con la tabla comparativa presentada por el examinador, ninguno de los documentos del arte previo enseñan o sugieren un compuesto de quinolinilo opcionalmente sustituido en la posición A.

Por lo tanto, el nuevo capítulo reivindicatorio adjunto es novedoso por sobre el estado del arte.

7. Falta de Nivel Inventivo


El examinador objeta el nivel inventivo de las reivindicaciones 11 – 20 a la luz de lo divulgado por la anterioridad D1, argumentando que “*La diferencia entre la invención, definida en la reivindicación 1 y los compuestos de D1 es que se encuentra un ligando L, que puede ser $-NR^bC(O)-$, $-(CR^cR^c)_m-C(O)-$, $OC(O)-$ o $-(CR^cR^c)_m-OC(O)-$* ”. El examinador concluye que para un experto con habilidad en la materia sería obvio incorporar un grupo separado no voluminoso entre el anillo de piperazina y el sustituyente R1.

El respecto, el solicitante quisiera anotar que, contrario a lo establecido por el examinador, para cualquier experto con habilidad en la materia es bien conocido

que la inclusión de cualquier elemento que afecte la geometría y la distribución espacial de un inhibidor o modulador de la actividad de una enzima puede tener un efecto negativo sobre la actividad de dicho compuesto y su capacidad de unirse a los sitios activos de la molécula que desea modular. De hecho, el que la molécula no vea su actividad afectada por la presencia de este nuevo grupo es, de por sí, un efecto sorprendente e inesperado a la luz de los conocimientos básicos del experto con habilidad ordinaria en la materia.

Por otro lado, el nuevo capítulo reivindicatorio adjunto también enseña que el sustituyente A es quinolinilo opcionalmente sustituido, cosa que tampoco es enseñada por el estado del arte. Esto quiere decir que los compuestos reclamados presentan otra diferencia al reemplazar un quinixalinilo sustituido por quinolinilo, lo cual implica una modificación adicional a la geometría de la molécula.

Así mismo, los compuestos de la presente solicitud difieren de los compuestos de



D1 en más detalles. Por ejemplo, el grupo carbonilo entre y el anillo aromático abarcado por las variables W, X, Y y Z en la fórmula (I) no se encuentra en ninguno de los compuestos de D1 que tienen un anillo de piperazina. Los ejemplos 130, 137, 146 y 149 son los únicos compuestos que tienen un anillo de piperazina; sin embargo la parte que correspondería al grupo carbonilo de la presente solicitud es un grupo metileno en los ejemplos 130, 137 y 149. El ejemplo 146 difiere de las nuevas reivindicaciones adjuntas en que los grupos sulfonilo y carbonilo están unidos en la posición meta del anillo aromático abarcado por las variables W, X, Y y Z en la posición para.


Más aún, la anterioridad D1 no enseña ni sugiere al experto con habilidad en la materia que los compuestos allí reclamados puedan, o deban, ser modificados ni mucho menos las modificaciones que podrían llevarse a cabo en los compuestos allí divulgados para obtener los compuestos de la presente invención. El solicitante considera que el examinador no ofrece argumentos técnicos debidamente sustentados que soporten sus objeciones. La inclusión de un grupo L como el de la presente solicitud solo es obvia, a la luz de los argumentos del examinador, si se realiza un estudio retrospectivo de la invención. El examinador no muestra exactamente en que se basaría el “la persona del oficio versada en la materia” para incluir los grupos espaciadores de la presente invención y no cualquier otro grupo de entre las cientos de miles de posibilidades que existen.

En resumen, me permito decir que gracias a las modificaciones expuestas en el punto 1 de este memorial y los argumentos anteriormente mencionados, la presente solicitud cumple cabalmente con los requisitos de patentabilidad,

claridad, unidad, novedad y nivel inventivo respecto los compuestos expuestos en el capítulo reivindicatorio adjunto. Por lo tanto, solicito comedidamente a ese despacho se sirva reconocer estos requisitos y conceder el privilegio de patente de invención a la solicitud en estudio.

En consecuencia, solicitamos a ese despacho pronunciarse en relación con todos los argumentos presentados en este memorial dando estricta aplicación al principio del debido proceso consagrado en el artículo 29 de la Constitución Nacional. De igual forma, si el examinador considera que subsisten razones para objetar la presente invención ruego expedir otro examen de fondo con los debidos motivos y razones que sustenten su objeción con el fin de que mi mandante tenga la posibilidad de exponer sus argumentos con base en la interpretación de los artículos 45 de la Decisión 486 -el cual otorga la facultad al examinador para emitir los exámenes de fondo-, 35 y 59 del Código Contencioso Administrativo que señala que: *“habiéndose dado oportunidad a los interesados para expresar sus opiniones, y con base en las pruebas e informes disponibles, se tomará la decisión que será motivada al menos en forma sumaria si afecta a particulares”* y *“(.) deberá proferirse la decisión definitiva. Esta se motivará en sus aspectos de hecho y de derecho, y en los de conveniencia si es el caso”*, respectivamente (el subrayado es nuestro).

Señor Superintendente,



SILVANA MARIA LÓPEZ DÍAZ


C.C. 22.468.787 de Barranquilla

T.P. 147463 del CSJ

notificaciones@clarkemodet.com.co

REIVINDICACIONES

1. Un compuesto de la fórmula (I)



o una sal del mismo farmacéuticamente aceptable, caracterizado porque

W, X, Y y Z son cada uno independientemente seleccionados a partir de CH o N;

D y D¹ son independientemente seleccionados a partir de un enlace o NR^b;

A es quinolinilo opcionalmente sustituido;

L es un enlace, -C(O)-, -(CR^cR^g)_m-, -OC(O)-, -(CR^cR^g)_m-OC(O)-, -(CR^cR^g)_m-C(O)-, -NR^bC(S)-, o -NR^bC(O)-;

R¹ se selecciona a partir de C1-C12 alquilo, C3-C12 cicloalquilo, arilo, heteroarilo de 4 a 14 miembros, y heterociclilo de 3 a 14 miembros; cada uno de los cuales es sustituido con 0-5 incidencias de R^d;

cada R³ se selecciona independientemente a partir de halo, C1-C12 haloalquilo, C1-C12 alquilo, hidroxilo y -OR^a o dos R³ adyacentes tomados junto con los átomos de carbono a los cuales están unidos, forman un ciclilo opcionalmente sustituido;

cada R^a se selecciona independientemente a partir de C1-C12 alquilo, acilo, C1-C12 hidroxialquilo y C1-C12 haloalquilo;

cada R^b se selecciona independientemente a partir de hidrógeno y C1-C12 alquilo;

cada R^c se selecciona independientemente a partir de hidrógeno, halo, C1-C12 alquilo, C1-C12 alcoxi y C1-C12 haloalcoxi o dos R^c tomados junto con los átomos de carbono a los cuales están unidos, forman un C3-C12 cicloalquilo opcionalmente sustituido;

cada R^d se selecciona independientemente a partir de halo, C1-C12 haloalquilo, C1-C12 haloalcoxi, C1-C12 alquilo, C2-C12 alquinilo, nitro, ciano, hidroxilo, -C(O)R^a, -OC(O)R^a, -C(O)OR^a, -SR^a, -NR^aR^b y -OR^a, o dos R^d tomados junto con los átomos de carbono a los cuales están unidos, forman un heterociclilo de 3 a 14 miembros opcionalmente sustituido;

n es 0, 1, o 2;

m es 1, 2 o 3;

h es 0, 1, 2; y

g es 0, 1 o 2.

2. El compuesto de conformidad con la reivindicación 1, caracterizado porque h es 1 y g es 1.

3. El compuesto de conformidad con la reivindicación 2, o una sal farmacéuticamente aceptable del mismo, caracterizado porque W, X, Y y Z son CH.

4. El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 3, o una sal farmacéuticamente aceptable del mismo, caracterizado porque D es NR^b y D^1 es un enlace.

5. El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 4, o una sal farmacéuticamente aceptable del mismo, caracterizado porque R^b es H, metilo o etilo.

6. El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 5, o una sal farmacéuticamente aceptable del mismo, caracterizado porque L es un enlace y R1 es alquilo, arilo o heteroarilo sustituido con 0 – 5 incidencias de R^d .

7. El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 5, o una sal farmacéuticamente aceptable del mismo, caracterizado porque L es $-(\text{CR}^e\text{R}^f)_m-$ y R1 es cicloalquilo, arilo, heteroarilo o heterociclilo con 0 – 5 incidencias de R^d .

8. El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 5, o una sal farmacéuticamente aceptable del mismo, caracterizado porque L es $-\text{NR}^b\text{C}(\text{O})-$, R^b es hidrógeno y R1 es arilo sustituido con 0 – 5 incidencias de R^d .

9. El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 5, o una sal farmacéuticamente aceptable del mismo, caracterizado porque L es $-(\text{CR}^e\text{R}^f)_m-\text{C}(\text{O})-$ y R1 es cicloalquilo, arilo o heteroarilo sustituido con 0 – 5 incidencias de R^d .

10. El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 5, o una sal farmacéuticamente aceptable del mismo, caracterizado porque L es $-\text{C}(\text{O})-$ y R1 es alquilo, arilo o heteroarilo sustituido con 0 – 5 incidencias de R^d .

11. El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 5, o una sal farmacéuticamente aceptable del mismo, caracterizado porque L es $-\text{OC}(\text{O})-$ y R1 es alquilo, arilo o heterociclilo sustituido con 0 – 5 incidencias de R^d .


12. El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 5, o una sal farmacéuticamente aceptable del mismo, caracterizado porque L es $-(\text{CR}^e\text{R}^f)_m-\text{OC}(\text{O})-$ y R1 es heterociclilo o cicloalquilo sustituido con 0 – 5 incidencias de R^d .

13. El compuesto de conformidad con cualquiera de las reivindicaciones 1 – 12 o una sal farmacéuticamente aceptable del mismo, caracterizado porque n es 0.


14. El compuesto de conformidad con cualquiera de las

reivindicaciones 1 – 12 o una sal farmacéuticamente aceptable del mismo, caracterizado porque n es 1 y R^3 es CH_3 , CH_2CH_3 , OCH_3 , OCH_2CH_3 , OH , F , Cl , o CF_3 .





















15. El compuesto de conformidad con cualquiera de las reivindicaciones 1 – 14 o una sal farmacéuticamente aceptable del mismo, caracterizado porque el compuesto es un compuesto de la fórmula (Id):













































16. El compuesto de conformidad con cualquiera de las reivindicaciones 1 – 15 o una sal farmacéuticamente aceptable del mismo, caracterizado porque A es:







































17. El compuesto de conformidad con la reivindicación 1 caracterizado porque el compuesto se selecciona del grupo que consiste de:















	
	
	
	
	
	
	
	
	
	



















	
	
	
	
	
	
	
	
	
	
	



















	
	
	
	
	
	
	
	
	
	



















	
	
	
	
	
	
	
	
	



















	
	
	
	
	
	
	
	
	



















	
	
	
	
	
	
	



















	
	
	
	
	
	
	
	
	



















	
	
	
	
	
	
	
	
	



















	
	
	
	
	
	
	
	
	



















	
	
	
	
	
	
	
	
	



















	
	
	
	
	
	
	
	
	



















	
	
	
	
	
	
	
	
	





















	
	
	
	
	
	
	
	
	





















	
	
	
	
	
	
	
	
	























	
	
	
	
	
	
	
	
	





















	
	
	
	
	
	
	
	
	























	
	
	
	
	
	
	
	
	


	
	
	
	
	
	
	
	
	
	


	
	
	
	
	
	
	
	
	
	





















	
	
	
	
	
	
	
	
	
	
	





















	
	
	
	
	
	
	
	
	
	



















	
	
	
	
	
	
	
	
	
	
	










































	
	
	
	
	
	
	
	
	
	

























	
	
	
	
	
	
	
	
	























O una sal farmacéuticamente aceptable del mismo.





















18. El compuesto de conformidad con la reivindicación 1, caracterizado porque el compuesto se selecciona del grupo que consiste de:























--	--





















40


	
	
	
	
	
	
	
	
	
	
	





















	
	
	
	
	
	
	
	
	
	
	


	
	
	
	
	
	
	
	
	
	


	
	
	
	
	
	
	
	
	
	
	




	
	
	
	
	
	
	
	
	
	






O una sal farmacéuticamente aceptable del mismo.

19. El compuesto de conformidad con la reivindicación 1, o una sal farmacéuticamente aceptable del mismo, en donde el compuesto se selecciona del grupo que consiste de:





20. Una composición farmacéutica que comprende un compuesto de conformidad con cualquiera de las reivindicaciones 1 – 19, o una sal farmacéuticamente aceptable de estos.